Curasan AG has signed an exclusive agreement with Ascension Orthopaedics Inc, Austin/Texas (USA), for the distribution of Cerasorb Ortho, a company release said.
The licence granted covers Cerasorb granules and block forms for applications within the area of orthopaedics, with the exception of the spine market. In parallel, the sales partnership established with Cryolife Inc for Cerasorb granules was discontinued. This decision was prompted by Cryolife's relaunch of its own product portfolio, which meant that sufficient sales capacity for Cerasorb would no longer be available.
"Cerasorb stands for progress in bone surgery," said Hans Dieter Rossler, CEO of curasan AG. "The cooperation with Ascension Orthopaedics will unlock new opportunities for both companies," he added.
"Distribution of Cerasorb in the US will provide us with greater leverage when it comes to exploiting growth opportunities in the burgeoning orthopaedics market," said Jerome Klawitter, CEO of Ascension Orthopaedics.
Ascension Orthopaedics Inc is involved in research, design, development, and marketing of orthopaedic solutions aimed at replacing the small skeletal joints of the hand, upper extremity, and foot.